William Copalu

ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model

Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision

The re-emergence of natural products for drug discovery in the genomics era

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

Eribulin Mesylate (E7389): Review of Efficacy and Tolerability in Breast, Pancreatic, Head and Neck, and Non–Small Cell Lung Cancer

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

Eribulin mesylate: A novel halichondrin B analogue for the treatment of metastatic breast cancer

Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box

Natural product and natural product derived drugs in clinical trials

Osteosarcoma: Current Treatment and a Collaborative Pathway to Success

Prescribed drugs containing nitrogen heterocycles: an overview

Developing a new formulation of sodium phenylbutyrate

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin

A phase I dose finding study of E7080 in patients (pts) with advanced malignancies

Eribulin mesylate pharmacokinetics in patients with hepatic impairment.

CYP2C9 and CYP2C19 Polymorphic Forms Are Related to Increased Indisulam Exposure and Higher Risk of Severe Hematologic Toxicity